The effect of intravenous and oral contrast on the SUV in 18F-FDG PET-CT

The effect of intravenous and oral contrast on the SUV in 18F-FDG PET-CT - The effect of intravenous and oral contrast on the SUV in 18F-FDG PET-CT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32605

Enrollment

Registered

2008-12-12

Start date

2008-09-15

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lymfomen (HD en NHL), cervixcarcinoma calculation of the uptake intensity of radioactive sugar among different scan circumstances in 18F-FDG PET-CT imaging

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -18F-FDG PET-CT indication with i.v. and/ or oral contrast; eg. staging, restaging, therapy monitoring or radiotherapy planning of malignancy -expected circumscript malignancy (eg. lung cancer, lymphomas or cervical cancer) -informed consent

Exclusion criteria

Exclusion criteria: Age

Design outcomes

Primary

Measure	Time frame
De differences in SUV measurements with and without contrast agents will be determined.	—

Secondary

Measure	Time frame
not appilcable	—

Countries

Netherlands

Outcome results